Peter Maag, Ph.D.

Peter Maag, Ph.D.

Former Chief Executive OfficeratKyverna Therapeutics· In proxies 2023–2024

Pay in FY2024-35% from the year before

Peter Maag, Ph.D. was paid $1.5M in FY2024 (Dec), down 35%.

PayNo stock prices for these years
Pay is from the Summary Compensation Table of each Kyverna Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Kyverna TherapeuticsPublic company · 3 yr
    • Former Chief Executive Officer2023 – Present · 3 yrStock in role -80%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?